GWA
ACAD icon

Gibson Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Gibson Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$98K Buy
6,300
+6,200
+6,200% +$96.9K ﹤0.01% 101
2022
Q3 		$2K Hold
100
– – ﹤0.01% 100
2022
Q2 		$1K Hold
100
– – ﹤0.01% 104
2022
Q1 		$2K Hold
100
– – ﹤0.01% 110
2021
Q4 		$2K Buy
+100
New +$2.01K ﹤0.01% 94

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Gibson Wealth Advisors's ACAD Position: Q4 2022 in Review

Gibson Wealth Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 6,200% in Q4 2022, buying an estimated $96.9K and bringing the position to 6,300 shares worth $98K. The position accounts for ﹤0.01% of the portfolio, ranked #101.

Gibson Wealth Advisors first reported a position in ACAD in Q4 2021 and has held it in 5 quarters since. 227 funds tracked by Wall St. Rank hold ACAD as of Q4 2022.

  • Gibson Wealth Advisors held 6,300 shares of Acadia Pharmaceuticals worth $98K as of Q4 2022.
  • Gibson Wealth Advisors bought 6,200 Acadia Pharmaceuticals shares in Q4 2022, an estimated $96.9K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Gibson Wealth Advisors's portfolio in Q4 2022, its #101 holding.
  • Gibson Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
  • 227 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2022.

Based on Gibson Wealth Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.